Xencor

Publications

• Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY (2007)
  Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discovery Today 12(21-22): 898-910.
• Zhu M.M., Mollet M., and Hubert R.S. (2007)
  Industrial Production of Therapeutic Proteins: Cell Lines, Cell Culture, and Purification. Industrial Chemistry and Biotechnology, Edited by Kent and Riegel, 11th Edition, Chapter 32, p1421-1448, Springer Press, The Netherlands.
• Jonathan Zalevsky, Thomas Secher, Sergei A. Ezhevsky, Laure Janot, Paul M. Steed, Christopher O'Brien, Araz Eivazi, James Kung, Duc-Hanh T. Nguyen, Stephen K. Doberstein, Francois Erard, Bernhard Ryffel, and David E. Szymkowski (2007)
  Dominant-Negative Inhibitors of Soluble TNF Attenuate Experimental Arthritis without Suppressing Innate Immunity to Infection. The Journal of Immunology 179, 1872-1883.
• Lazar G.A., Desjarlais J.R., Jacinto J., Karki S., and Hammond P.W. (2007)
  A molecular immunology approach to antibody humanization and functional optimization. Molecular Immunology 44, 1986-1998.
• Lazar G.A., Dang W., Karki S., Vafa O., Peng J.S., Hyun L., Chan C., Chung H.S., Eivazi A., Yoder S.C., Vielmetter J., Carmichael D.F., Hayes R.J., and Dahiyat, B.I. (2006)
  Engineered Antibody Fc Variants with Enhanced Effector Function. Proc Natl Acad Sci USA 103(11), 4005-4010.
• Barbosa, M.D.F.S., Vielmetter, J., Seung, C., Smith, D.D., and Jacinto, J. (2006)
  Clinical link between MHC class II haplotype and interferon-beta (IFN-B) immunogenicity. Clinical Immunology, 118, 42-50
• Szymkowski D.E. (2005)
  Creating the next generation of protein therapeutics through rational drug design. Current Opinion in Drug Discovery & Development 8(5), 590-600
• Vielmetter J. et al. (2005)
  Data management solutions for protein therapeutic research and development, Drug Discovery Today: Biosilico, 10(15), 1065-1071
• Szymkowski D.E. (2005)
  Timely lessons for target-based discovery of anti-inflammatory drugs. Drug Discovery Today, 109(1), 14-17
• Szymkowski D.E. (2004)
  Rational optimization of proteins as drugs: A new era of 'medicinal biology'. Drug Discovery Today, 9(9), 381-383
• Zhukovsky E.A. and Morse R.J. (2004)
  Pleiotropy: the BAFFling truth of the TNF superfamily. Drug Discovery Today: Targets, vol.3, No. 6, pp. 225-227
• Chirino A. J. and Mire-Sluis A. (2004)
  Characterizing biological products and assessing comparability following manufacturing changes. Nature Biotechnology, 22(11), 1383-91
• Zhukovsky E.A., Lee J.O., Villegas M., Chan C., Chu S., Mroske C. (2004)
  TNF ligands: is TALL-1 a trimer or a virus-like cluster? Nature, 427(6973), 413-4
• Chirino, A.J., Ary, M.L., Marshall, S.A. (2004)
  Minimizing the immunogenicity of protein therapeutics. Drug Discovery Today, 9(2), 82-90
• Steed, P.M. et al. (2003)
  Inactivation of TNF Signaling by Rationally Designed Dominant-Negative TNF Variants. Science, 301, 1895-1898(Full Text)
• Lazar, G.A., Marshall, S.A., Plecs, J.J., Mayo, S.L., Desjarlais, J.R. (2003)
  Designing proteins for therapeutic applications. Curr Opin Struct Biol, 13(4), 513-8
• Szymkowski D.E. (2003)
  Chemical genomics versus orthodox drug development. Drug Discovery Today, 8(4), 157-159
• Marshall, S.A., Lazar, G.A., Chirino, A.J., Desjarlais, J.R., (2003)
  Rational design and engineering of therapeutic proteins. Drug Discovery Today, 8(5), 212-2
• Filikov, A.V., Hayes, R.J., Luo, P., Stark, D.M., Chan, C., Kundu, A., and Dahiyat, B.I. (2002)
  Computational stabilization of human growth hormone. Protein Science, 11, 1452
• Hayes, R.J., Bentzien, J., Ary, M.L., Hwang, M.Y., Jacinto, J.M., Vielmetter, J., Kundu, A., and Dahiyat, B.I. (2002)
  Combining computational and experimental screening for rapid optimization of protein properties. Proc Natl Acad Sci USA, 99, 15926
• Luo, P, Hayes, R.J., Chan, C., Stark, D.M., Hwang, M.Y., Jacinto, J. M., Juvvadi, P., Chung, H.S., Kundu, A., Ary, M.L., and Dahiyat, B.I. (2002)
  Development of a cytokine analog with enhanced stability using computational ultrahigh throughput screening. Protein Science, 11(5), 1218
• Dahiyat, B. I., (1999)
  In silico design for protein stabilization. Curr. Op. Biotechnol., 10, 387
• Malakauskas, S. M., and Mayo, S. L., (1998)
  Design, structure and stability of a hyperthermophilic protein variant. Nature Struc. Biol., 5, 470
• Dahiyat, B. I., and Mayo, S. L., (1997)
  Probing the role of packing specificity in protein design. Proc Natl Acad Sci U S A, 94, 10172
• Dahiyat, B., Gordon, D., and Mayo, S. L. (1997)
  Automated design of the surface of protein helices. Protein Sci., 6, 1333
• Dahiyat, B. I., and Mayo, S. L., (1997)
  De novo protein design: fully automated sequence selection. Science, 278, 82
• Dahiyat, B. I., and Mayo, S. L., (1996)
  Protein design automation. Protein Sci., 5, 895